Nitromed CFO Kenneth Bate will succeed interim CEO Jerry Karabelas, the company announces Jan. 22. Bate joined Nitromed in March as part of a management shake-up to jump-start sales of the firm's heart failure therapy for African Americans, BiDil (1"The Pink Sheet" March 27, 2006, p. 14). Bate has held vice president positions at Millennium and Biogen Idec...
You may also be interested in...
NitroMed's strategy for jump-starting sales of BiDil includes renewed efforts to get favorable formulary placement for the heart failure drug
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.